Table 1.
Demographic and clinical characteristics of AIIRD patients in the Israeli Rheumatologic COVID-19 registry.
| Variable* | 1st-3rd outbreaks n=302 | 4th outbreak n=110 | All n=412 |
|---|---|---|---|
| Covid-19 outbreak | |||
| First (March-May 2020) | 24 (7.9) | ||
| Second (June-October 2020) | 158 (52.3) | ||
| Third (November 2020-April 2021) | 120 (39.7) | ||
| Fourth (July-November 2021) | 110 | ||
| Age (years) mean(SD) | 53.7 (15.4) | 50.1 (14.7) | 52.8 (15.3) |
| Female n (%) | 214 (70.8) | 80 (72.7) | 295 (71.6) |
| AIIRD diagnosis | |||
| RA | 100 (33.1) | 29 (26.4) | 129 (31.3) |
| SpA (including PsA and AS) | 61 (20.2) | 27 (24.5) | 88 (21.4) |
| SLE | 41 (13.6) | 17 (15.5) | 58 (14.1) |
| Other CTD (SSc, IIM, MCTD, etc.) | 30 (9.9) | 19 (17.3) | 49 (11.9) |
| Vasculitis | 32 (10.6) | 10 (9.1) | 42 (10.2) |
| FMF | 19 (6.2) | 2 (1.8) | 21 (5.1) |
| Sarcoidosis | 12 (4.0) | 1 (0.9) | 13 (3.2) |
| Other AIIRD | 7 (2.3) | 5 (4.5) | 12 (2.9) |
| Any systemic involvement | 130 (43.0) | 42 (38.2) | 172 (41.7) |
| Lung involvement | 39 (12.9) | 16 (14.5) | 55 (13.3) |
| Cardiac involvement | 23 (7.6) | 7 (6.3) | 30 (7.3) |
| Renal involvement | 27 (8.9) | 9 (8.2) | 36 (8.7) |
| Vascular involvement | 55 (18.2) | 24 (21.8) | 79 (19.2) |
| AIIRD disease duration (years) median (IQR) (N=295) | 10 (5, 15) | 7 (4,15) | 10 (4,15) |
| Current immunomodulatory treatment | |||
| Prednisone | 120 (39.7) | 33 (30) | 153 (37.1) |
| csDMARDs | 176 (58.3) | 53 (48.2) | 230 (55.8) |
| MTX | 73 (24.2) | 14 (12.7) | 87 (21.1) |
| MMF/MPA | 22 (7.3) | 9 (0.82) | 31 (7.5) |
| Biologic or targeted synthetic medication | 136 (45.0) | 62 (56.3) | 198 (48.1) |
| Anti-cytokines* | 32 (10.6) | 35 (31.8) | 67 (16.3) |
| Rituximab | 24 (7.9) | 16 (14.5) | 40 (9.7) |
| Abatacept | 5 (1.7) | 4 (3.6) | 9 (2.2) |
| JAK i | 14 (4.6) | 4 (3.6) | 18 (4.4) |
| Comorbidities | 194 (64.2) | 71 (64.5) | 265 (64.3) |
| More than 1 comorbidity | 80 (26.5) | 27 (24.5) | 107 (26.0) |
| IHD | 11 (3.6) | 4 (2.7) | 15 (3.6) |
| Hypertension | 83 (27.5) | 20 (18.2) | 103 (25.0) |
| Diabetes Mellitus | 56 (18.5) | 14 (12.7) | 70 (17.0) |
| Congestive heart failure | 10 (3.3) | 5 (4.5) | 15 (3.6) |
| Chronic renal failure | 19 (6.3) | 5 (4.5) | 24 (5.8) |
| Obesity | 63 (20.9) | 18 (16.4) | 81 (20.0) |
| Chronic lung disease (COPD, asthma) | 31 (10.3) | 10 (9.1) | 41 (10.0) |
| Atherosclerosis and AF | 16 (5.3) | 11 (10) | 27 (6.6) |
| Smoking (ever) | 13 (4.3) | 8 (7.3) | 21 (5.1) |
*Categorical variables are presented as number (%). Normally distributed continuous variables are presented as mean ± SD and skewed continues variables are presented as median (IQR).
AIIRD, autoimmune inflammatory rheumatic disease; COVID-19, coronavirus disease 2019; n, number; SD, standard deviation; RA, rheumatoid arthritis; SpA, spondyloarthritis; PsA, psoriatic arthritis; AS, ankylosing spondylitis; SLE, systemic lupus erythematosus; CTD, connective tissue disease; SSc, systemic sclerosis; IIM, idiopathic inflammatory myopathy; MCTD, mixed connective tissue disease; FMF, familial Mediterranean fever; IQR, interquartile range; csDMARDs, conventional synthetic disease modifying anti-rheumatic drugs; MTX; methotrexate, MMF, mycophenolate mofetil; MPA, mycophenolic acid; JAKi, Janus-kinase inhibitors; IHD, ischemic heart disease; COPD, chronic obstructive pulmonary disease; AF, atrial fibrillation.